With the brand name of Onpattro, Patisiran is the only FDA-approved RNA interference (RNAi) drug targeting polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR) (Adams et al., 2018). The gene discussed is TTR; the disease is amyloidosis.